Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03193502

Enrollment

Registered

2017-06-20

Start date

2014-05-01

Completion date

2020-12-31

Last updated

2017-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal Vein Thrombosis

Brief summary

-Rivaroxaban is factor Xa inhibitor

Detailed description

PVT is a common complication of liver cirrhosis

Interventions

DRUGrivaroxaban

rivaroxaban

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Acute PVT

Exclusion criteria

* Malignant PVT * Bleeding disorders

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with recanalized portal vein	6 months	recanalization of portal vein

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, consultant

Sheriefabdelsalam@yahoo.com00201095159522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026